Press Release-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

NEWS Press Release Media Report

Year:

Select

Press Release

13 December 2019

9966. HK - Remain true to our original aspiration and start our next journey We warmly celebrate that Alphamab Oncology’s successful listing in Hong Kong!
23 October 2019

Dr. Ting Xu Presides over Scientist Forum; Alphamab Oncology Appears at the 11th China Pharmaceutical Conference for Entrepreneurs, Scientists and Investors Alphamab Oncology was invited to the conference, and Dr. Ting Xu, the Founder, Chairman and CEO of the company, was invited to preside over the Scientist Forum. Dr. Xu shared his experience and insigh...
11 September 2019

KN046 Research Findings to be Presented at CSCO 2019 Alphamab Oncology announced that two clinical study abstracts of KN046, an innovative PD-L1/CTLA-4 bispecific antibody, were received by the Annual Meeting of Chinese Society of Clinical Oncology (CSC...
06 September 2019

A Phase II Clinical Trial Launched for KN046 in Combination with Chemotherapy in Advanced NSCLC Alphamab Oncology, a leading clinical-stage biopharmaceutical company in China, announced today that a phase II clinical study has been launched for KN046 in combination with chemotherapy to evaluate ...
26 June 2019

Alphamab Oncology Initiates the US Phase I Clinical Trial for KN026 SUZHOU, China, June 26, 2019 - Alphamb Oncology announced that KNO26, an anti-HER2 bispecific antibody independently developed by the company, has entered phase I clinical trial in the United States a...
18 June 2019

Alphamab Oncology Initiated KN046 Phase Ib/II Clinical Trial in TNBC SUZHOU, China, June 18, 2019 – Alphamab Oncology announced that KN046, an innovative PD-L1/CTLA-4 bispecific antibody developed by the company has made new progress.
06 June 2019

Alphamab Oncology Initiated KN026 Phase II Clinical Trial Alphamab Oncology announced that KN026, an anti-HER2 bispecific antibody independently developed by the company, has entered phase II clinical trial in patients with advanced gastric or gastroesophage...
29 May 2019

Alphamab Oncology Announces Completion of US$60 Million Series B Financing SUZHOU, China, May 28, 2019 - Alphamab Oncology, a leading biopharmaceutical company dedicated to global development of innovative biologics for cancer therapy, announced today that it has completed a...
20 May 2019

Alphamab Oncology Initiates Phase II Clinical Trial of KN046 in Patients with Advanced Unresectable or Metastatic Esophageal Squamous Cell Carcinoma SUZHOU, China, May 20, 2019 - A phase II clinical trial to evaluate the efficacy, safety and tolerability of KN046 in patients with advanced unresectable or metastatic esophageal squamous cell carcino...
20 May 2019

KN019’s Phase II Clinical Study Protocol Symposium was Successfully Held in Beijing SUZHOU, China, May 20, 2019 - A phase II clinical study protocol symposium of KN019, a fusion protein composed of the Fc-fragment of a human IgG1 immunoglobulin linked to the extracellular domain of C...

15 16 17 18 19 20